HIV Treatment And Long-Acting Therapy Preferences Overview Recent developments in long-acting antiretroviral therapy (LA-ART) offer promising prospects for enhancing HIV treatment by addressing adherence challenges. However, the success of these regimens depends on their acceptance among people living with HIV (PWH). To investigate patient preferences regarding LA-ART options, we conducted a discrete
Internal Medicine
Idiopathic Parkinson’s Tremors: Treatment Options
Idiopathic Parkinson's Tremors: Treatment Options The study examines the clinical importance of tremors in idiopathic Parkinson's disease (iPD) and the difficulties encountered in their management. It underscores the diversity of iPD patients and the various symptoms they experience, notably tremors, which significantly affect their quality of life. Despite historical efforts to
Bipolar Disorder And The Impact Of Insulin Sensitivity
Bipolar Disorder And The Impact Of Insulin Sensitivity Overview This study investigated the impact of insulin resistance (IR) and insulin sensitivity on various brain parameters in individuals with bipolar disorder (BD). Bipolar disorder is associated with structural and functional brain changes, and BD patients have an increased risk of developing insulin resistance,
Blue Light Therapy For Melasma Patients
Blue Light Therapy For Melasma Patients Melasma, a common skin pigmentation condition, presents as distinctive brown spots on the face, notably affecting individuals with darker skin tones. Although the exact causes remain elusive, factors such as solar radiation, genetics, and hormonal fluctuations are believed to play pivotal roles. Solar radiation, including
Insulin Therapy for Wound Healing: A Meta-Analysis
Insulin Therapy for Wound Healing: A Meta-Analysis Overview Insulin, known for its affordability and widespread availability, has emerged as a promising agent in the realm of wound healing. This study delved into the potential of local insulin administration to facilitate the recovery of damaged skin among non-diabetic adults. To achieve this, a
Cabozantinib Therapy In Hepatocellular Carcinoma
Cabozantinib Therapy In Hepatocellular Carcinoma Hepatocellular carcinoma (HCC) is a predominant form of liver cancer, accounting for approximately 90% of cases. Unfortunately, it carries a grim prognosis, with a median survival rate ranging from 6 to 18 months. Historically, sorafenib had been the established first-line therapy for HCC. However, in recent
Obese Children And Related Skin Conditions
Obese Children And Related Skin Conditions The World Health Organization defines overweight and obesity based on the body mass index (BMI), which is calculated as weight (kg) divided by height (m2). When assessing overweight and obesity in children, it's important to consider their age and gender. To do this, percentile curves
PD-1/L1 Inhibitors: Treatment Efficacy In Urothelial Carcinoma
PD-1/L1 Inhibitors: Treatment Efficacy In Urothelial Carcinoma Overview Programmed cell death‐1/ligand 1 (PD-1/PD-L1) inhibitors represent a novel therapeutic approach for advanced urothelial carcinoma, prompting the need for a comparative assessment of their effectiveness and safety in comparison to traditional chemotherapy. To address this, a comprehensive meta-analysis of randomized controlled trials conducted until
Encapsulated Papillary Carcinoma Membrane Characteristics
Encapsulated Papillary Carcinoma Membrane Characteristics Overview This study focused on encapsulated papillary carcinoma (EPC), a type of breast carcinoma characterized by a thick fibrous capsule-like structure surrounding the tumor, often interpreted as a thickened basement membrane (BM). The primary objective was to investigate the geometric properties of the EPC capsule and determine
Ibrutinib Treatment In Waldenström Macroglobulinemia
Ibrutinib Treatment In Waldenström Macroglobulinemia Waldenström macroglobulinemia (WM) is a rare type of non-hogdkins lymphoma driven by the gene mutation MYD88L265P. Ibrutinib, the first approved treatment, is effective but can cause side effects. A study found that 27% of WM patients needed to reduce Ibrutinib doses due to side effects like
